Wall Street analysts expect that Johnson & Johnson (NYSE:JNJ) will report $20.21 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Johnson & Johnson’s earnings. The lowest sales estimate is $20.07 billion and the highest is $20.62 billion. Johnson & Johnson posted sales of $18.11 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.6%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, January 23rd.

According to Zacks, analysts expect that Johnson & Johnson will report full year sales of $20.21 billion for the current year, with estimates ranging from $76.21 billion to $80.09 billion. For the next fiscal year, analysts expect that the company will report sales of $81.56 billion per share, with estimates ranging from $80.72 billion to $82.66 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same period last year, the business posted $1.68 earnings per share. Johnson & Johnson’s quarterly revenue was up 10.3% compared to the same quarter last year.

JNJ has been the subject of several research analyst reports. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. Royal Bank of Canada raised their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Citigroup initiated coverage on shares of Johnson & Johnson in a report on Monday, September 25th. They issued a “neutral” rating and a $140.00 price objective for the company. Goldman Sachs Group lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and raised their price objective for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. Finally, Jefferies Group upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the stock from $145.00 to $157.00 in a report on Wednesday, October 11th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $145.04.

Shares of Johnson & Johnson (NYSE JNJ) opened at $142.46 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $144.35. The company has a market cap of $381,940.00, a PE ratio of 20.02, a price-to-earnings-growth ratio of 2.90 and a beta of 0.80.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s dividend payout ratio is 58.33%.

Several hedge funds and other institutional investors have recently made changes to their positions in JNJ. Parametric Portfolio Associates LLC increased its position in shares of Johnson & Johnson by 3.3% during the third quarter. Parametric Portfolio Associates LLC now owns 8,026,652 shares of the company’s stock valued at $1,043,545,000 after acquiring an additional 253,568 shares in the last quarter. Karpus Management Inc. bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $231,000. Wagner Bowman Management Corp increased its position in shares of Johnson & Johnson by 3.2% during the third quarter. Wagner Bowman Management Corp now owns 47,171 shares of the company’s stock valued at $6,132,000 after acquiring an additional 1,452 shares in the last quarter. Hikari Tsushin Inc. increased its position in shares of Johnson & Johnson by 8.3% during the third quarter. Hikari Tsushin Inc. now owns 53,810 shares of the company’s stock valued at $6,996,000 after acquiring an additional 4,130 shares in the last quarter. Finally, Burgundy Asset Management Ltd. increased its position in shares of Johnson & Johnson by 0.4% during the third quarter. Burgundy Asset Management Ltd. now owns 3,195,878 shares of the company’s stock valued at $415,496,000 after acquiring an additional 11,257 shares in the last quarter. 65.89% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/16/brokerages-expect-johnson-johnson-jnj-will-announce-quarterly-sales-of-20-21-billion.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.